Eye Drops Proven To Reverse Vision Loss In Clinical Trial
Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically significant improvement in distance-corrected near visual acuity of a 3-line or greater gain. In addition, CSF-1 demonstrated an exceptional safety and tolerability profile.
Jeff discusses the value of OIS for the venture community and the success of Visionary Ventures.
“We are excited to initiate the Phase 2b clinical trial evaluating our corrective eye drop as it marks a key milestone in its clinical development,” said Elad Kedar, chief executive officer of Orasis. “CSF-1 has the potential to restore near-vison and offer an alternative to current treatment options, which are either cumbersome or invasive. We look forward to sharing the results from this study in the near future as we advance the development of CSF-1 in the clinic for the treatment of presbyopia, a condition that affects more than 1.8 billion people worldwide.”
The Phase 2b study (NCT03885011) is a multi-center, double-masked trial in the U.S. enrolling 150 participants with presbyopia to evaluate the efficacy and safety of CSF-1. The study started enrolling patients in February 2019. All study sites are actively recruiting participants aged 45 to 64 with presbyopia.
Orange County-based VC Visionary Ventures Fund 1 last week released its 2018 executive summary showing it closed the year with a 33% internal rate of return, ranking it among the top performing VC funds in the U.S.
Alcon acquires Visionary portfolio company Tear Film Innovations to expand its portfolio in Dry Eye.
Zeiss acquires Visionary portfolio company IanTECH to expand its portfolio in cataract surgery.
Orasis announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors.